Candidate leukemia genes identified in this MuLV screen
| CIS group*/Gene hit† . | Annotation . | Tumor panel‡ . | ||
|---|---|---|---|---|
| Nf1+ . | Evi2 . | Nf1− . | ||
| I | ||||
| Edg3 | Endothelial differentiation, sphingolipid G protein–coupled receptor, 3 | 0 | 1 | 1 |
| ENS#1 | Unknown | 2 | 1 | 1 |
| FLJ20186 | Differentially expressed in FDCP 8 | 1 | 0 | 2 |
| Ing1 | Inhibitor of growth protein 1 | 1 | 1 | 1 |
| Etnk1 | Ethanolamine kinase 1 | 1 | 0 | 1 |
| II | ||||
| Bcl11a | B-cell CLL/lymphoma 11A | 0 | 3 | 2 |
| Spred2 | Sprouty protein with EVH-1 domain 2, related sequence | 0 | 1 | 4 |
| Pmaip1 | Phorbol-12-myristate-13-acetate–induced protein 1 | 1 | 1 | 0 |
| Jund1 | Jun proto-oncogene–related gene d1 | 1 | 0 | 1 |
| III | ||||
| Ahi1/Myb | WD domain and SH3 domain–containing gene | 6 | 4 | 4 |
| Hoxa7/a9 | Homeobox A7/A9 | 2 | 0 | 2 |
| Meis1 | Myeloid ecotropic viral integration site 1 | 3 | 0 | 2 |
| IV | ||||
| Usp21 | Ubiquitin-specific protease 21 | 1 | 0 | 0 |
| Enah | Enabled homolog | 1 | 0 | 0 |
| Tlr2 | Toll-like receptor 2 | 1 | 0 | 0 |
| Btbe3 | Basic transcription element–binding protein 3 | 0 | 1 | 0 |
| Sar1a | GTP-binding protein Sar1a | 1 | 0 | 0 |
| Fgd3 | Faciogenital dysplasia homolog 3 | 1 | 0 | 0 |
| Pilrb | Paired immunoglobulin-like type 2 receptor beta | 0 | 0 | 1 |
| Foxd1 | Forkhead box protein D1 | 0 | 1 | 0 |
| Gata2 | GATA-binding protein 2 | 1 | 0 | 0 |
| Olig2 | Oligodendrocyte transcription factor 2 | 1 | 0 | 0 |
| Wnt7a | Wingless-type MMTV integration site family, member 7A | 1 | 0 | 0 |
| Ly86 | Lymphocyte antigen 86 | 0 | 1 | 0 |
| ENS#2 | Unknown | 0 | 0 | 1 |
| V | ||||
| ENS#3 | Similar to eosinophil chemotactic cytokine | 0 | 1 | 0 |
| Nfkb1 | Nuclear factor NF-κ-B p105 subunit | 1 | 0 | 0 |
| Centg3 | Centaurin, gamma 3 | 1 | 0 | 0 |
| Dyrk1b | Dual-specificity tyrosine-(Y) phosphorylation-regulated kinase 1b | 1 | 0 | 0 |
| Tbx21 | T cell–specific T-box transcription factor T-bet | 0 | 1 | 0 |
| Lyl1 | Lymphoblastomic leukemia | 1 | 0 | 0 |
| Cbfa2t3h | Core-binding factor, runt domain, alpha subunit 2 | 1 | 0 | 0 |
| PHF5A | PHD finger protein 5A | 0 | 0 | 1 |
| Runx1 | Runt-related transcription factor 1 | 0 | 1 | 0 |
| Tcirg1 | T-cell, immune regulator 1 | 0 | 1 | 0 |
| Lin28 | RNA-binding protein LIN-28 | 0 | 0 | 1 |
| Emid2 | EMI domain–containing protein 2 | 0 | 0 | 1 |
| ATP5G2 | ATP synthase, H+ transporting, mitochondrial complex, subunit C2 | 0 | 1 | 0 |
| Ifngr1 | Interferon-γ receptor 1 | 0 | 0 | 1 |
| Atp5g2 | ATP synthase lipid-binding protein, mitochondrial precursor | 0 | 0 | 1 |
| Vegfb | Vascular endothelial growth factor B | 0 | 0 | 1 |
| Lmo2 | LIM domain only 2 | 1 | 0 | 0 |
| Akt1 | v-akt murine thymoma viral oncogene homolog 1 | 0 | 1 | 0 |
| CIS group*/Gene hit† . | Annotation . | Tumor panel‡ . | ||
|---|---|---|---|---|
| Nf1+ . | Evi2 . | Nf1− . | ||
| I | ||||
| Edg3 | Endothelial differentiation, sphingolipid G protein–coupled receptor, 3 | 0 | 1 | 1 |
| ENS#1 | Unknown | 2 | 1 | 1 |
| FLJ20186 | Differentially expressed in FDCP 8 | 1 | 0 | 2 |
| Ing1 | Inhibitor of growth protein 1 | 1 | 1 | 1 |
| Etnk1 | Ethanolamine kinase 1 | 1 | 0 | 1 |
| II | ||||
| Bcl11a | B-cell CLL/lymphoma 11A | 0 | 3 | 2 |
| Spred2 | Sprouty protein with EVH-1 domain 2, related sequence | 0 | 1 | 4 |
| Pmaip1 | Phorbol-12-myristate-13-acetate–induced protein 1 | 1 | 1 | 0 |
| Jund1 | Jun proto-oncogene–related gene d1 | 1 | 0 | 1 |
| III | ||||
| Ahi1/Myb | WD domain and SH3 domain–containing gene | 6 | 4 | 4 |
| Hoxa7/a9 | Homeobox A7/A9 | 2 | 0 | 2 |
| Meis1 | Myeloid ecotropic viral integration site 1 | 3 | 0 | 2 |
| IV | ||||
| Usp21 | Ubiquitin-specific protease 21 | 1 | 0 | 0 |
| Enah | Enabled homolog | 1 | 0 | 0 |
| Tlr2 | Toll-like receptor 2 | 1 | 0 | 0 |
| Btbe3 | Basic transcription element–binding protein 3 | 0 | 1 | 0 |
| Sar1a | GTP-binding protein Sar1a | 1 | 0 | 0 |
| Fgd3 | Faciogenital dysplasia homolog 3 | 1 | 0 | 0 |
| Pilrb | Paired immunoglobulin-like type 2 receptor beta | 0 | 0 | 1 |
| Foxd1 | Forkhead box protein D1 | 0 | 1 | 0 |
| Gata2 | GATA-binding protein 2 | 1 | 0 | 0 |
| Olig2 | Oligodendrocyte transcription factor 2 | 1 | 0 | 0 |
| Wnt7a | Wingless-type MMTV integration site family, member 7A | 1 | 0 | 0 |
| Ly86 | Lymphocyte antigen 86 | 0 | 1 | 0 |
| ENS#2 | Unknown | 0 | 0 | 1 |
| V | ||||
| ENS#3 | Similar to eosinophil chemotactic cytokine | 0 | 1 | 0 |
| Nfkb1 | Nuclear factor NF-κ-B p105 subunit | 1 | 0 | 0 |
| Centg3 | Centaurin, gamma 3 | 1 | 0 | 0 |
| Dyrk1b | Dual-specificity tyrosine-(Y) phosphorylation-regulated kinase 1b | 1 | 0 | 0 |
| Tbx21 | T cell–specific T-box transcription factor T-bet | 0 | 1 | 0 |
| Lyl1 | Lymphoblastomic leukemia | 1 | 0 | 0 |
| Cbfa2t3h | Core-binding factor, runt domain, alpha subunit 2 | 1 | 0 | 0 |
| PHF5A | PHD finger protein 5A | 0 | 0 | 1 |
| Runx1 | Runt-related transcription factor 1 | 0 | 1 | 0 |
| Tcirg1 | T-cell, immune regulator 1 | 0 | 1 | 0 |
| Lin28 | RNA-binding protein LIN-28 | 0 | 0 | 1 |
| Emid2 | EMI domain–containing protein 2 | 0 | 0 | 1 |
| ATP5G2 | ATP synthase, H+ transporting, mitochondrial complex, subunit C2 | 0 | 1 | 0 |
| Ifngr1 | Interferon-γ receptor 1 | 0 | 0 | 1 |
| Atp5g2 | ATP synthase lipid-binding protein, mitochondrial precursor | 0 | 0 | 1 |
| Vegfb | Vascular endothelial growth factor B | 0 | 0 | 1 |
| Lmo2 | LIM domain only 2 | 1 | 0 | 0 |
| Akt1 | v-akt murine thymoma viral oncogene homolog 1 | 0 | 1 | 0 |
CIS group indicates the way CISs were identified for the corresponding genes. CISs that are composed of at least 2 insertions positioned within 20-kb pairs isolated in this study, and no insertions (I), single insertions (II), or known CISs (III) have previously been reported. IV and V indicate single insertions isolated in this study for which known single insertions (IV) or CISs (V) can be found.
Gene hits indicate genes located nearby CISs, which were determined according to the annotation for the mouse genome (http://www.ensembl.org). ENS#1 indicates ENSMUSG00000019986; ENS#2, ENSMUSG00000030553; and ENS#3, ENSMUSG00000010135.
Tumor panel denotes the genotype of leukemia from which the corresponding proviral insertions were recovered. Nf1+ indicates tumors with intact Nf1 alleles; Evi2, tumors with Nf1 alleles disrupted by Evi2 insertion; and Nf1−, tumors with engineered null Nf1 allele. Values are the number of insertions isolated from each genotype of leukemia.